Title |
Lung cancer and chronic obstructive pulmonary disease: From a clinical perspective
|
---|---|
Published in |
Oncotarget, January 2017
|
DOI | 10.18632/oncotarget.14505 |
Pubmed ID | |
Authors |
Jie Dai, Ping Yang, Angela Cox, Gening Jiang |
Abstract |
Chronic obstructive pulmonary disease (COPD) and lung cancer are devastating pulmonary diseases that commonly coexist and present a number of clinical challenges. COPD confers a higher risk for lung cancer development, but available chemopreventive measures remain rudimentary. Current studies have shown a marked benefit of cancer screening in the COPD population, although challenges remain, including the common underdiagnosis of COPD. COPD-associated lung cancer presents distinct clinical features. Treatment for lung cancer coexisting with COPD is challenging as COPD may increase postoperative morbidities and decrease survival. In this review, we outline current progress in the understanding of the clinical association between COPD and lung cancer, and suggest possible cancer prevention strategies in this patient population. |
Twitter Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 33% |
Practitioners (doctors, other healthcare professionals) | 1 | 33% |
Members of the public | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 101 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 21 | 21% |
Student > Master | 11 | 11% |
Student > Ph. D. Student | 9 | 9% |
Student > Doctoral Student | 6 | 6% |
Researcher | 6 | 6% |
Other | 21 | 21% |
Unknown | 27 | 27% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 32 | 32% |
Biochemistry, Genetics and Molecular Biology | 10 | 10% |
Nursing and Health Professions | 5 | 5% |
Agricultural and Biological Sciences | 4 | 4% |
Unspecified | 3 | 3% |
Other | 17 | 17% |
Unknown | 30 | 30% |